2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-12096A
    WAY-207024 dihydrochloride 872002-73-8 98%
    WAY-207024 (dihydrochloride) is a potent and orally active GnRH antagonist that reduces leuteinizing hormone (LH) levels in plasma.
    WAY-207024 dihydrochloride
  • HY-121045
    Bunitrolol 34915-68-9
    Bunitrolol hydrochloride is an orally active β-adrenergic blocker that has a high affinity for β-adrenergic receptors. Bunitrolol hydrochloride exerts significant β-receptor antagonist activity and has weak α1-blocking activity. Bunitrolol hydrochloride is mainly used in the study of cardiovascular diseases such as hypertension and angina pectoris, and is also used in placental transport research.
    Bunitrolol
  • HY-121088
    Ceefourin 2 348148-51-6 98%
    Ceefourin 2 is a potent and highly selective inhibitor of MRP4. Ceefourin 2 inhibits the transport of MRP4 substrates but is not selective for other ABC transporters. Ceefourin 2 shows lower cytotoxicity and higher microsomal and acid stability.
    Ceefourin 2
  • HY-121183
    Aprikalim 132562-26-6 98%
    Aprikalim (RP 52891), a potassium channel opener (KCO), activates ATP-sensitive K+ (KATP) channels in guinea pig ventricular myocytes. Using patch-clamp techniques, it was found that aprikalim enhances KATP channel activity more effectively in Mg-NDP solution compared to standard solutions. In Mg-NDP solution, aprikalim reduced the sensitivity of KATP channels to ATP, increasing the concentration of ATP required to inhibit channel activity by half (K1) from 56 μM to 180 μM. However, this effect diminished over time. Aprikalim's ability to activate KATP channels in Mg-NDP solution suggests potential therapeutic implications in modulating cardiac excitability and may relate to changes in channel protein enzymatic activity under experimental conditions.
    Aprikalim
  • HY-121215
    Chloracyzine 800-22-6 98%
    Chloracyzine is an antianginal agent with spasmolytic properties and prevent or relieve spasms of the coronary vessels. Chloracyzine shows a moderate antihistaminic effect.
    Chloracyzine
  • HY-121232
    Delapril 83435-66-9 98%
    Delapril (CV-3317) is an orally active angiotensin I converting enzyme (ACE) inhibitor. Delapril has antihypertensive activity.
    Delapril
  • HY-121259
    Doxorubicinol 54193-28-1 98%
    Doxorubicinol, a potent inhibitor of the cardiac sarcoplasmic reticulum calcium pump, inhibits systolic myocardial function in isolated heart muscle. Doxorubicinol inhibits tumor cell growth and has cardiotoxicity.
    Doxorubicinol
  • HY-121311
    Metrenperone 81043-56-3 98%
    Metrenperone is an inhibitor for 5-HT2 receptor. Metrenperone exhibits α1 and α2 antagonist activity as well as anti-H1 and anti-dopaminergic efficacy. Metrenperone can lower the blood pressure, enhances bradycardia in peripheral ischemia, inhibits serotonin-induced platelet aggregation, and antagonizes serotonin-mediated vasoconstriction. Metrenperone promotes the repair of acutely damaged collagen tissue.
    Metrenperone
  • HY-121312
    Flutonidine 28125-87-3 98%
    Flutonidine (ST-600) is a Clonidine (HY-12721) analogue that shows antihypertensive and sympatholytic effects. The initial hypertension produced by Flutonidine is due to stimulation of the peripheral α1, α2 adrenoceptors and the subsequent fall in blood pressure is due to the stimulation of central α2 adrenoceptors. Flutonidine reduces the arrhythmogenic and lethal effects of ouabain. Flutonidine is promising for research of ventricular arrhythmias caused by cardiac glycosides.
    Flutonidine
  • HY-121354
    Hydracarbazine 3614-47-9 98%
    Hydracarbazine is a pyridazine. Hydracarbazine can effectively lower blood pressure, it can be used for the research of high blood pressure.
    Hydracarbazine
  • HY-121394
    L-659,989 113787-28-3 98%
    L-659,989 is an orally active, extremely potent, selective and competitive platelet activating factor (PAF) receptor antagonist.
    L-659,989
  • HY-121460
    Spiraprilat 83602-05-5 98%
    Spiraprilat is a potent angiotensin-converting enzyme (ACE) inhibitor. Spiraprilat has ability to improve left ventricular (LV) function and metabolism in anesthetized open-chest dogs with acute ventricular failure (ALVF).
    Spiraprilat
  • HY-121519
    GSK2332255B 1366233-41-1 98%
    GSK2332255B is a potent, selective TRPC3 and TRPC6 antagonist with IC50s of 5 nM and 4 nM for rat TRPC3 and rat TRPC6. GSK2332255B shows ≥100-fold selectivity for TRPC3/6 over other calcium-permeable channels.
    GSK2332255B
  • HY-121520
    Docosahexaenoyl glycine 132850-40-9 98%
    Docosahexaenoyl glycine is a PUFA analogue. Docosahexaenoyl glycine has activating effects on IKs channels and restore the function of IKs channels with LQT1 mutation.
    Docosahexaenoyl glycine
  • HY-121550
    ME3221 139958-16-0 98%
    ME3221 is an angiotensin AT1 receptor antagonist that effectively antagonizes the pressor response to angiotensin II in rats and marmosets without affecting the hypotensive response to bradykinin. It demonstrates potent antihypertensive effects in renal hypertensive rats and spontaneously hypertensive rats (SHR), with efficacy comparable to or better than losartan in vivo. ME3221's repeated administration in SHR results in sustained and stable hypotensive effects without affecting heart rate, indicating its potential for treating both renal and essential hypertension similarly to losartan.
    ME3221
  • HY-121586
    Nafazatrom 59040-30-1 98%
    Nafazatrom (Bay g 6575) is an orally active cardioprotective agent that protects against ischemic damage. Nafazatrom dose-dependently inhibits neutrophil aggregation, superoxide anion generation, arachidonic acid metabolism, and to a lesser extent the release of β-glucosidase, platelet aggregation or arachidonic acid in vitro. Acid metabolism has no significant effect. In a dog ischemia-reperfusion model, Nafazatrom (10 mg/kg; po) reduced infarct size and the occurrence of arrhythmias and rescued ischemic myocardial function without affecting any hemodynamic changes. The basis of Nafazatrom's cardioprotection may be inhibition of neutrophil function and cellular infiltration in vitro.
    Nafazatrom
  • HY-121598
    Actisomide 96914-39-5 98%
    Actisomide (SC-36602) is an antiarrhythmic agent. Absorption of actisomide in rats and its in vitro uptake in CaCo-2 cells are pH-dependent.
    Actisomide
  • HY-121609
    Pholedrine 370-14-9 98%
    Pholedrine, the main metabolite of methamphetamine, is an indirectly acting sympathomimetic amine. Pholedrine is a cardiovascular agent exerting hypertensive and adrenergic effects. Pholedrine can produce mydriatic response and allow localization of the site of the interruption in the oculosympathetic pathway. Pholedrine can be used as a topical eye drop and a diagnostic agent for use in Horner's syndrome.
    Pholedrine
  • HY-121617
    Bucainide 51481-62-0 98%
    Bucainide (RHC G-233) is an antiarrhythmic agent that enables the determination of Bucainide in plasma using the GLC method.
    Bucainide
  • HY-121690
    Semotiadil 116476-13-2 98%
    Semotiadil (SD-3211), a benzothiazine compound, is a Ca2+ antagonist. Semotiadil exerts antiplatelet activity.
    Semotiadil
Cat. No. Product Name / Synonyms Application Reactivity